Federated Hermes, Inc. Oncocyte Corp Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.25 - $15.6 $288 - $18,002	1,154 Added 47.69%	3,574 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $1,839 - $38,671	2,420 New	2,420 $2,000
Q2 2020 Aug 13, 2020	SELL	$1.91 - $3.45 $893 - $1,614	-468 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$1.76 - $3.02 $62,583 - $107,388	-35,559 Reduced 98.7%	468 $1,000
Q4 2019 Feb 14, 2020	BUY	$1.51 - $2.27 $54,400 - $81,781	36,027 New	36,027 $81,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $241M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.